• Amanda van Beinum, Laura Hornby, Tim Ramsay, Roxanne Ward, Sam D Shemie, and Sonny Dhanani.
• Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Canada amandavb4@gmail.com.
• J Intensive Care Med. 2016 May 1; 31 (4): 243-51.

ObjectiveThe process of controlled donation after circulatory death (cDCD) is strongly connected with the process of withdrawal of life-sustaining therapy. In addition to impacting cDCD success, actions comprising withdrawal of life-sustaining therapy have implications for quality of palliative care. We examined pilot study data from Canadian intensive care units to explore current practices of life-sustaining therapy withdrawal in nondonor patients and described variability in standard practice.DesignSecondary analysis of observational data collected for Determination of Death Practices in Intensive Care pilot study.SettingFour Canadian adult intensive care units.PatientsPatients ≥18 years in whom a decision to withdraw life-sustaining therapy was made and substitute decision makers consented to study participation. Organ donors were excluded.InterventionsNone.Measurements And Main ResultsProspective observational data on interventions withdrawn, drugs administered, and timing of life-sustaining therapy withdrawal was available for 36 patients who participated in the pilot study. Of the patients, 42% died in ≤1 hour; median length of time to death varied between intensive care units (39-390 minutes). Withdrawal of life-sustaining therapy processes appeared to follow a general pattern of vasoactive drug withdrawal followed by withdrawal of mechanical ventilation and extubation in most sites but specific steps varied. Approaches to extubation and weaning of vasoactive drugs were not consistent. Protocols detailing the process of life-sustaining therapy withdrawal were available for 3 of 4 sites and also exhibited differences across sites.ConclusionsStandard practice of life-sustaining therapy withdrawal appears to differ between selected Canadian sites. Variability in withdrawal of life-sustaining therapy may have a potential impact both on rates of cDCD success and quality of palliative care.© The Author(s) 2015.

25 keywords...

hide…